Medicare covers Ozempic the way it covers most brand drugs: through a Part D plan or a Medicare Advantage plan with drug coverage, for the uses on its label [1]. That means type 2 diabetes. The $50 Medicare GLP-1 Bridge that started in July 2026 is a separate program for weight management, and Ozempic isn't in it [2].
| Your situation | Ozempic covered? | What you pay | Source |
|---|---|---|---|
| Type 2 diabetes, with Part D or a Medicare Advantage drug plan | Yes, if it's on your plan's drug list or approved through the plan's exception process | Your plan's cost share; out-of-pocket for covered drugs capped at $2,100 in 2026 | [4] [6] |
| No diabetes, prescribed a GLP-1 for weight loss | No. The GLP-1 Bridge may cover Foundayo, Wegovy or Zepbound KwikPen instead if you qualify | $50 a month for a Bridge drug | [2] [3] |
| Medicaid | Depends on your state; BALANCE states may also cover GLP-1s for weight management | Set by your state's program | [8] [7] |
| January 1, 2027 onward | Same coverage rules; the negotiated price changes what Medicare pays | Still your plan's cost share; cap rises to $2,400 | [5] [6] |
Medicare and CMS figures as currently published.
Does Medicare cover Ozempic?
Yes, through Part D or a Medicare Advantage plan with drug coverage, when it's prescribed for type 2 diabetes. Ozempic's label lists three uses, all in adults with type 2 diabetes: improving blood sugar alongside diet and exercise, lowering the risk of heart attack, stroke and cardiovascular death in people who already have heart disease, and lowering the risk of kidney decline and cardiovascular death in people who also have chronic kidney disease [1].
CMS spelled out in June 2026 that plans keep covering GLP-1 drugs for those uses. Its guidance says Part D sponsors "must continue to provide coverage of GLP-1 drugs for indications that are currently coverable under Medicare Part D" and must keep following "their existing formulary exception processes" [4]. In plain terms, if Ozempic isn't on your plan's drug list, your prescriber can still ask the plan for an exception.
Plans differ on the details. Some require prior authorization or ask you to try another diabetes drug first. Those rules live in your own plan's drug list, so check it before you assume a cost.
What you'll pay in 2026
Your Part D costs move through three stages and stop at $2,100 for the year. First comes the deductible, if your plan has one; no plan's deductible can be more than $615 in 2026 [6]. Then Medicare.gov describes 25% coinsurance until your out-of-pocket spending on covered drugs reaches $2,100. After that you're in catastrophic coverage and pay nothing more for covered Part D drugs that year [6].
| Stage | 2026 | 2027 | What happens |
|---|---|---|---|
| Deductible (maximum) | $615 | $700 | You pay full cost until it's met; some plans have none |
| Initial coverage | 25% coinsurance | 25% coinsurance | You share the cost until the out-of-pocket cap |
| Out-of-pocket cap | $2,100 | $2,400 | Catastrophic coverage: $0 for covered Part D drugs for the rest of the year |
Source: Medicare.gov, "Costs for Medicare drug coverage." Your plan's copays may differ within these limits.
The cap counts all your covered drugs together, not Ozempic alone. If you take several brand drugs, you may reach it early in the year. Medicare.gov also points to the Medicare Prescription Payment Plan as one way to manage those costs [2]. Our monthly cost calculator turns any plan's billing into a monthly total.
Why Medicare doesn't cover Ozempic for weight loss
Medicare drug coverage generally leaves out drugs used for weight loss, and Ozempic isn't approved for weight loss anyway. CMS says it directly: "currently Medicare and Medicaid generally do not cover these drugs for the weight loss indication" [7]. Ozempic's own label lists only type 2 diabetes uses [1].
The weight-management brands of the same drug classes are Wegovy (semaglutide, the same molecule as Ozempic), Zepbound (tirzepatide) and Foundayo (orforglipron, a daily pill). Those are the drugs the Bridge covers. You can read more on the Wegovy and Zepbound guides.
The Medicare GLP-1 Bridge, and why Ozempic isn't in it
From July 1, 2026, eligible Part D enrollees can get Wegovy, Zepbound KwikPen or Foundayo for $50 a month, but not Ozempic [2]. The program runs through December 31, 2027 [3]. It sits outside the normal Part D benefit, so your plan doesn't have to opt in.
| Item | What Medicare says |
|---|---|
| Covered drugs | Foundayo (tablet); Wegovy (injection or tablet); Zepbound KwikPen only, not single-dose vials or pens |
| Dates | July 1, 2026 through December 31, 2027 |
| Your cost | $50 copay a month |
| Who qualifies | Age 18+ with Part D, and a BMI of 35+; or 30+ with heart failure with preserved ejection fraction, uncontrolled high blood pressure or chronic kidney disease stage 3a or higher; or 27+ with prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease |
| Who doesn't | People whose Part D plan already covers their GLP-1, and people with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease (their Part D plan may cover a GLP-1 instead) |
| Paperwork | A prescription plus prior authorization when requested; the prescriber certifies a diet-and-exercise lifestyle program; approval lasts through December 31, 2027 unless you switch GLP-1s |
| Counts toward your costs? | No. The deductible doesn't apply, the $50 doesn't count toward the $2,100 cap, and Extra Help doesn't reduce it |
Sources: Medicare.gov "Weight loss drugs" and the CMS Medicare GLP-1 Bridge page.
The type 2 diabetes exclusion is the part that matters most for Ozempic users. CMS's FAQ says a person with a diagnosis Part D already covers, such as type 2 diabetes, isn't eligible for the Bridge "even if the beneficiary otherwise meets the Medicare GLP-1 Bridge clinical criteria" [4]. If you have diabetes, your route stays your regular Part D plan.
If you don't have diabetes and want a GLP-1 for weight, the Bridge is the Medicare route to look at. The full cost picture for each brand is on our Wegovy cost and Zepbound cost pages.
Already on Ozempic through Medicare? The Bridge doesn't change your route
If your plan already pays for Ozempic, nothing about the Bridge moves you. Medicare.gov says people whose GLP-1 is paid for by their Medicare drug plan aren't eligible for the Bridge, "but you can keep getting your GLP-1 drug through your current plan" [2].
Switching brands doesn't open the door either. CMS's FAQ takes the exact case of someone on a GLP-1 for type 2 diabetes who is later prescribed Wegovy or Zepbound for weight management. The answer is no: a person with a Part D-coverable diagnosis such as type 2 diabetes is not eligible, and a prior authorization request that lists one "will be denied" [4].
One more trap: discount cards. Medicare.gov notes that discount cards and cash-price sites aren't creditable coverage, so what you pay through them "doesn't count toward your Medicare deductible or out-of-pocket maximum" [2]. A cash price can look lower in January and still cost you more over the year if it keeps you from reaching the $2,100 cap.
What changes in 2027
Medicare's negotiated price for Ozempic, Rybelsus and Wegovy takes effect January 1, 2027 [5]. CMS negotiated $274 for a 30-day supply, against a 2024 list price of $959. That's 71% lower. About 2.28 million Part D enrollees used one of the three drugs in 2024 [5].
The negotiated price is what Medicare and plans pay for the drug. Your own share still depends on your plan's deductible and coinsurance, so it won't simply be $274. Coinsurance is a percentage of the price, though, so a lower price can lower what you pay in that stage. The 2027 deductible rises to a maximum of $700, and the out-of-pocket cap to $2,400 [6].
Two other 2027 points: CMS has said its BALANCE model won't launch in Medicare in 2027, and it extended the Bridge through December 31, 2027 to cover that gap [3]. Rybelsus, the pill form of semaglutide, shares the negotiated price; the pill options are explained on our oral semaglutide guide.
Does Medicaid cover Ozempic?
Medicaid drug coverage is run by each state, so the answer for Ozempic depends on where you live. Federal law makes pharmacy coverage optional, but Medicaid.gov says "all states currently provide coverage for outpatient prescription drugs to all categorically eligible individuals and most other enrollees" [8]. Each state decides which brands are preferred and which need prior authorization.
For weight management, CMS's BALANCE model adds a second path. States can join between May 2026 and January 1, 2027. CMS negotiates price and eligibility terms with drugmakers on their behalf [7]. The model lists "all formulations of Mounjaro, Ozempic, Rybelsus, and Wegovy, the KwikPen formulation of Zepbound, and Foundayo" for both type 2 diabetes and weight management uses [7]. Ozempic's own label still covers type 2 diabetes only [1].
How to check your own coverage
- Look up Ozempic in your plan's drug list (formulary) and note its tier and any prior authorization rule.
- Use Medicare's plan finder to compare plans that cover it at a lower cost share.
- Call 1-800-MEDICARE (TTY 1-877-486-2048) for Bridge eligibility or prior authorization status [2].
- On Medicaid, ask your state Medicaid office or plan for its preferred drug list, and whether your state joined BALANCE.
If you're paying cash or have commercial insurance, the numbers are different; see what Ozempic costs without insurance. For the drug's warnings and side effects, read Ozempic safety and side effects.
Weighing programs on price? The brand Wegovy and Zepbound self-pay programs lineup sets 21 of them side by side, each with its true monthly cost.